Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 11/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21425603 | 0.86 | KCNH2 (0.43) | EPHX1KDM1AMAOBSLC6A2SLC6A4 | |
| SCHEMBL28363633 | 0.84 | EPHX1 (0.35) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL28363635 | 0.84 | EPHX1 (0.35) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL34470892 | 0.84 | EPHX1 (0.35) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL3237330 | 0.84 | EPHX1 (0.50) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL2693563 | 0.81 | — | — | |
| SCHEMBL1955385 | 0.81 | EPHX1 (0.48) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL20500000 | 0.81 | EPHX1 (0.37) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL20500003 | 0.81 | EPHX1 (0.37) | EPHX1GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL4239836 | 0.80 | EPHX1 (0.39) | EPHX1GNAI3GNAO1GNAI1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | claimed |
| WO-2026087909-A1 | COMPOUNDS FOR USE AS NEUROPROTECTIVE AGENTS AND/OR IN INHIBITING FORMATION OF ALPHA-SYNUCLEIN AGGREGATES | AC IMMUNE SA (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4713093-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES | AC Immune SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024236059-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES | AC IMMUNE SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| CN-111699185-B | 6-azaindole compounds | 百时美施贵宝公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4041730-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-2513110-B1 | 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | EPHX1 1663/4885GNAI3 968/4885GNAO1 2325/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | EPHX1 1663/4885GNAI3 968/4885GNAO1 2325/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | EPHX1 1663/4885GNAI3 968/4885GNAO1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.